LB Pharmaceuticals Inc Common Stock
LBRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.07B
Close$
$9.75
71.3% downside
Current Fair Value
71.3% downsideOvervalued by 71.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.07 Billion |
|---|---|
| Enterprise Value | $789.45 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1 |
| Beta | 0.42 |
| Outstanding Shares | 30,137,000 |
Return
| Return on Equity | -25.78% |
|---|---|
| Return on Assets | -23.69% |
| Return on Invested Capital | -27.64% |
Valuation & Multiples
| P/E Ratio | -12.53 |
|---|---|
| PEG | -4.75 |
| Price to Sales | - |
| Price to Book Ratio | 3.09 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -8.45 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-1.62
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 106.06% |
|---|---|
| Total Invested | $13,548▼ 100.00% |
| Investors Holding | 3▼ 114.00% |
ESG Score
No data
About LB Pharmaceuticals Inc Common Stock
16 employees
CEO: Heather D. Turner Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.